Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
European Journal of Cancer (Oxford, England : 1990)|March 22, 2017
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapyLieve Brochez, Ines Chevolet, Vibeke KruseThe Lancet. Oncology|March 8, 2017
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trialMax Schreuer, Yanina Jansen, Simon Planken, et al.Journal of Cutaneous and Aesthetic Surgery|September 12, 2013
Hypomelanoses in childrenNanja van Geel, Marijn Speeckaert, Ines Chevolet, et al.The Australasian Journal of Dermatology|October 11, 2014
A short dermoscopy training increases diagnostic performance in both inexperienced and experienced dermatologistsInes Chevolet, Isabelle Hoorens, Astrid Janssens, et al.Oncoimmunology|July 4, 2012
Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanomaReinhart Speeckaert, Nanja Van Geel, Jo Lambert, et al.Journal of Translational Medicine|February 1, 2017
A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic responseKatrien De Wolf, Vibeke Kruse, Nora Sundahl, et al.JAMA Dermatology|October 15, 2015
Total-Body Examination vs Lesion-Directed Skin Cancer ScreeningIsabelle Hoorens, Katrien Vossaert, Lore Pil, et al.Journal of Translational Medicine|January 17, 2015
Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanomaInes Chevolet, Reinhart Speeckaert, Max Schreuer, et al.JAMA Dermatology|January 10, 2016
Comparison of Ex Vivo and In Vivo Dermoscopy in Dermatopathologic Evaluation of Skin TumorsMarc Haspeslagh, Katrien Vossaert, Sven Lanssens, et al.Melanoma Research|December 5, 2015
Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanomaMax Schreuer, Geert Meersseman, Sari van Den Herrewegen, et al.Pageof 2